Abstract Treatment of patients with hepatocellular carcinoma (HCC) in the advanced stage
remains a great challenge, with very few drugs approved. After decades of failure of immune …

Several anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies (Table 1) are currently being
investigated, alone and in combination, for the treatment of hepatocellular carcinoma (HCC) …

The discovery of the immune checkpoint mechanism has contributed greatly to recent
advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody …

Immunotherapy is a promising approach to treating various types of cancers, including
hepatocellular carcinoma (HCC). While single immunotherapy drugs show limited …

The introduction of immunotherapies has been a major development in the treatment of
many advanced cancers, including hepatocellular carcinoma (HCC). We are entering a new …

With mortality rates of liver cancer doubling in the last 20 years, this disease is on the rise
and has become the fifth most common cancer in men and the seventh most common …

Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of
disease. Until recently, systemic treatment options that showed survival benefits in HCC …

Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell
death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Hepatocellular carcinoma (HCC) is the most common liver cancer with high morbidity and
mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase …